FDA actions in brief, March 2008
A summary of drugs and indications recently approved by FDA: Intelence, Alvesco Inhalation Aerosol, Moxatag, Humira, Asmanex, Tekturna HCT, Herceptin
Etravirine (Intelence, Tibotec) was approved for use with other antiretroviral agents for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
Ciclesonide (Alvesco Inhalation Aerosol, Nycomed) was approved for the maintenance and prophylactic treatment of asthma in adult and adolescent patients aged ≥12 years.
Once-daily amoxicillin extended-release tablets (Moxatag, MiddleBrook) were approved for the treatment of adults and pediatric patients aged ≥12 years with pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes.
Mometasone inhalation powder (Asmanex Twisthaler, Schering-Plough) was approved for the maintenance treatment of asthma as a preventative therapy in patients aged 4 to 11 years.
Aliskiren/hydrochlorothiazide (Tekturna HCT, Novartis) was approved for the treatment of hypertension.
Trastuzumab (Herceptin, Genentech) was approved as adjuvant monotherapy for the treatment of early-stage HER2-positive breast cancer.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
